Compare DLTR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTR | RPRX |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 25.9B |
| IPO Year | 1996 | 2020 |
| Metric | DLTR | RPRX |
|---|---|---|
| Price | $121.13 | $58.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $123.35 | $51.40 |
| AVG Volume (30 Days) | ★ 3.4M | 2.8M |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 144.33 | N/A |
| EPS | ★ 1.76 | 0.67 |
| Revenue | ★ $19,411,800,000.00 | $2,378,193,000.00 |
| Revenue This Year | $8.48 | $38.63 |
| Revenue Next Year | $5.90 | $4.73 |
| P/E Ratio | ★ $66.85 | $88.09 |
| Revenue Growth | ★ 10.43 | 5.06 |
| 52 Week Low | $84.71 | $34.63 |
| 52 Week High | $142.40 | $59.44 |
| Indicator | DLTR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 59.32 |
| Support Level | $117.54 | $54.95 |
| Resistance Level | $132.87 | $58.84 |
| Average True Range (ATR) | 3.93 | 1.28 |
| MACD | -1.29 | 0.07 |
| Stochastic Oscillator | 21.95 | 77.36 |
Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2025, Dollar Tree generated over $19 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.